Your SlideShare is downloading. ×
Desembre activitat 2013
Desembre activitat 2013
Desembre activitat 2013
Desembre activitat 2013
Desembre activitat 2013
Desembre activitat 2013
Desembre activitat 2013
Desembre activitat 2013
Desembre activitat 2013
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Desembre activitat 2013

111

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
111
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Desembre 2013 Actualització farmacoterapèutica en Esclerosi Múltiple @APR_300
  • 2. Presentació Objectiu: recollir les novetats sobre farmacoteràpia de l’Esclerosi Múltiple publicats en les diferents revistes biomèdiques. En aquest document, hi podràs trobar reunits els tuits de cada mes del compte de Twitter @APR_300 per a una lectura més fàcil. La present informació està dirigida a professionals sanitaris. En cas que siguis un pacient, comenta qualsevol dubte amb un professional sanitari. Tipus d’informació: orientat a la farmacoteràpia i aspectes relacionats com la farmacogenètica o la farmacoeconomia i també alguns estudis de recerca bàsica. Filtre d’idioma: articles publicats en anglès, català o castellà. No hi ha conflictes d’interessos. No es pretén afavorir a cap fàrmac. El volum d’informació de cada apartat dependrà exclusivament del nombre d’articles publicats/ localitzats. Autora: Ariadna Pérez Ricart Farmacèutica hospitalària Twitter: @APR_300 Desembre 2013. Vol 1, Núm 2 @APR_300 Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.
  • 3. Aquest mes, notícies sobre: -Interferons -Acetat de glatiràmer -Fingolimod -Natalizumab -Laquinimod -Daclizumab -Alemtuzumab -Rituximab -Vitamina D -Espasticitat -Vacuna Bacille Calmette-Guérin -4-aminopiridina -Dalfampridine Fampridine / -Genètica -Pediatria -Embaràs Desembre 2013. Vol 1, Núm 2 @APR_300 Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.
  • 4. DESEMBRE 2013 Esdeveniments destacats: 15 de desembre: La Marató de TV3. Malalties neurodegeneratives. 18 de desembre: Dia Nacional de l’Esclerosi Múltiple Tuits: Interferons - Intramuscular IFNß-1a in multiple sclerosis: ‘no proof of effectiveness’ or ‘proof of no effectiveness’? http://bit.ly/18wkXdD Eur J Neurol - Assessing treatment response to interferon-β http://bit.ly/1cEgRPn Neurology - ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study http://1.usa.gov/19BRVnm Med Devices - Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-beta-1b: a case report. http://bit.ly/19ymfTF J Med Cas Rep -Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes http://bit.ly/1jNpvyr J Neur Neurosurg Psychiatry -Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. http://bit.ly/19fKyb2 J Neur Neurosurg Psychiatry Acetat de glatiràmer -Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. http://bit.ly/1cjLwkZ CNS Drugs Desembre 2013. Vol 1, Núm 2 @APR_300 Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.
  • 5. Fingolimod -Five-year results from a phase 2 study of oral fingolimod in relapsing remiting multiple sclerosis http://bit.ly/18Sp2GV Mult Scler - Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis bit.ly/1eDV8Xr Curr Med Res Opin - Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study http://bit.ly/1eQkB0C J Neurol - Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis via CIMSFHUVH http://bit.ly/1czgHc8 Eur J Clin Pharmacol Natalizumab - Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial multiple sclerosis http://bit.ly/1bc3xx1 Eur J Neurol -Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango http://bit.ly/1iwlFeO Expert Opin Biol Ther -A benefit-risk analysis of natalizumab in the treatment of pa tients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy http://bit.ly/1bGGj8w Curr Med Res Opin -Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients http://bit.ly/J2RmMh Mult Scler - Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning http://bit.ly/1aLolLV Mult Scler - Smokers run increased risk of developing anti-natalizumab antibodies http://bit.ly/IPnN0G Mult Scler - Risk acceptance in multiple sclerosis patients on natalizumab treatment. http://bit.ly/1c1hliE Plos One - Consenso español actualizado sobre el uso del natalizumab via CIMSFHUVH i BibliotecaHUVH http://bit.ly/1c3hrpT Neurologia Laquinimod -Multiple sclerosis: Oral laquinimod for MS—bringing the brain into focus http://bit.ly/1gJIvLU Nature Reviews Neurology Desembre 2013. Vol 1, Núm 2 @APR_300 Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.
  • 6. Daclizumab -Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis http://bit.ly/1d3qrtn Expert Rev Clin Pharmacol - Assessing dalfampridine efficacy in the physician’s office http://bit.ly/1bN5Kz6 Mult Scler - Effect of daclizumab high-yield process in patients with highly active relapsingremitting multiple sclerosis http://bit.ly/19UK7RA J Neurol Alemtuzumab -Current evaluation of alemtuzumab in multiple sclerosis. http://bit.ly/1g3vjUk Expert Opin Biol Ther Rituximab -Rituximab for relapsing-remitting multiple sclerosis. http://bit.ly/199urtv Cochrane Database Syst Rev Vitamina D -1,25-Dihydroxyvitamin D3 selectively and reversibly impairs T helper-cell CNS localization. http://1.usa.gov/1bWqV7Z Proc Nat Acad SCI USA Tractaments simptomàtics -Bladder management in MS http://bit.ly/1bDvp1A Phys Med Rehabil Clin N Am -Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I) http://bit.ly/1dYNxq3 Eur J Health Econ - Vision and multiple sclerosis http://bit.ly/IzkLya Multiple Sclerosis & related disorders -Pharmacological treatment for memory disorder in multiple sclerosis Cochrane Database Syst Rev http://bit.ly/1cl0REV -4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review http://bit.ly/1e3AQ91 Ther Adv Neurol Disord - Evidence-based guideline: Assessment and management of psychiatric disorders in individuals with MS http://bit.ly/KeX8LM Neurology Desembre 2013. Vol 1, Núm 2 @APR_300 Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.
  • 7. Tractaments simptomàtics -Espasticitat -Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study http://bit.ly/1b8DY3j Int J Neurosci -MultipleSclerosis spasticity epidemiology – key publications. http://bit.ly/1hryKEX Exp Rev Neurother -MultipleSclerosis spasticity management – key publications http://bit.ly/1j8StbM Exp Rev Neurother -Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice http//bit.ly/IDkRVK Exp Rev Neurother -Advances in the management of MultipleSclerosis spasticity: guidelines http://bit.ly/1b6YrXk Exp Rev Neurother -Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe http://bit.ly/1cgatOm Exp Rev Neurother -Dalfampridine / Fampridine -Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis http://bit.ly/18vTo47 Curr Med Res Opin -Long-term effects of dalfampridine in patients with multiple sclerosis. http://bit.ly/19fcwxO J Neurol Sci - Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis http://bit.ly/1bp3CNO Multiple Sclerosis & related disorders Transplantament hematopoiètic i noves teràpies - Identification of Inflammatory Neuronal Injury and Prevention of Neuronal Damage in Multiple Sclerosis. Hope for Novel Therapies? http://bit.ly/1d6r0T3 JAMA Neurol -Iron depletion induced by bloodletting and followed by rhEPO administration as a therapeutic strategy in progressive multiple sclerosis: A pilot, open-label study with neurophysiological measurements http://bit.ly/1c2T2fK Neurophysiol Clin -Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis http://bit.ly/J2QQxV Mult Scler - Effects of Bacille Calmette-Guérin vaccine after the first demyelinating event in the CNS multiple sclerosis http://bit.ly/1bhXln6 Neurology Genètica -Decoding multiple sclerosis: an update on genomics and future directions http://bit.ly/19chLOE Expert Rev Neurother -Body fluid biomarkers in multiple sclerosis http:// bit.ly/1gjp8f1 Lancet Neurol Desembre 2013. Vol 1, Núm 2 @APR_300 Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.
  • 8. Pediatria i Embaràs - Application of the 2012 revised diagnostic definitions for paediatric multiple sclerosis and immune-mediated central nervous system demyelination disorders http://bit.ly/1cubeDo J Neurol Neurosurg Psychiatry -Review of Safety-Related Pregnancy Data Surrounding the Oral Disease-Modifying Drugs for multiple sclerosis http://bit.ly/19aPSfS CNS Drugs Altres -Esclerosis múltiple en el contexto español http://bit.ly/1eIIVkd Rev Neurol -Risk evaluation and monitoring in multiple sclerosis therapeutics http://bit.ly/18SpCEL Mult Scler -Multiple sclerosis and related disorders: groundbreaking news http://bit.ly/1d4LawM Lancet Neurol - Treatment of multiple sclerosis in Germany: an analysis based on claims data of more than 30,000 patients http://bit.ly/1bvI4PT Int J Clin Pharm - A network meta-analysis of randomized controlled trials comparing the effectiveness and safety profile of treatments for relapsing multiple sclerosis via CIMSFHUVH http://bit.ly/1bMESQ3 J Clin Pharm Ther -New and emerging immune-targeted drugs for the treatment of multiple sclerosis. http://bit.ly/18BAfxn Br J Clin Pharmacol -Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. http://bit.ly/1dwuWg7 Biologics - Novel Immunomodulatory Approaches for the Management of multiple sclerosis via @velezmeca http://bit.ly/1l0MJyJ Clin Pharmacol Ther - Antimyelin antibodies as predictors of disability after clinically isolated syndrome http://bit.ly/1e65OgI Int J Neurosci -Impact of delayed diagnosis and treatment in clinically isolated syndrome and multiple sclerosis http://bit.ly/19aFO46 J Neurosci Nurs Desembre 2013. Vol 1, Núm 2 @APR_300 Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.
  • 9. Pacients -Esclerosis multiple en linea: Incontinencia urinaria. Vídeos per a pacients de @FundacioGaem -RT@neurodidacta: embarazo, lactancia o anticoncepción en esclerosis múltiple de la Dra Mar Mendibe http://bit.ly/IowXS8 vía @redpacientes -RT@VHIR_:El Dr. @XMontalban encercla l'esclerosi múltiple a Càpsules de Ciència Televisió de Catalunya: http://bit.ly/1cSOk6Z via @tv3cat -Lazo Múltiple: app per la difusió i la conscienciació sobre l'Esclerosis Múltiple http://bit.ly/1g7zKhd Agències de medicaments i altres notícies -Review of Dimethyl fumarate http://bit.ly/1eMhnKF AustPrescriber - Estudio de la retina para visualizar la evolución de la esclerosis múltiple via seneurologia http://bit.ly/1aPrD0L - La vitamina D podria aliviar los síntomas de la EM via fundcerebro http://bit.ly/18Ujnm2 Desembre 2013. Vol 1, Núm 2 @APR_300 Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.

×